Sector News

Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal

March 19, 2018
Life sciences

Lundbeck agreed to buy Prexton Therapeutics, a specialist in treatments for brain disorders, in a deal potentially worth $1.1 billion, the Danish drugmaker said on Friday.

Prexton has drug candidate foliglurax in phase II testing for treatment of Parkinson’s disease, with first data expected to be available in the first half of 2019.

Lundbeck, which develops and distributes drugs for neurological and psychological diseases, said it would pay 100 million euros ($123 million) up front for Prexton and make up to 805 million euros in development, regulatory and sales milestones payments.

Prexton was founded in 2012 by Francois Conquet and M Ventures, the corporate venture arm of Merck KGaA. M Ventures had still been one of Prexton’s largest shareholders, a Merck KGaA spokesman said.

Lundbeck said the deal would have no impact on its financial guidance for 2018.

“Parkinson is one of our focus areas, so this fits perfect into our strategy of buying early-stage drugs,” Lundbeck interim Chief Executive Anders Gotzsche told Reuters.

More than half of the 805 million euros in potential payments s connected to sales milestones, Lundbeck said.

“Several drugs are available on the market, but there is still unmet demand,” Gotzsche said.

Gotzsche, who stepped in as CEO after industry veteran Kare Schultz was hired by Teva in September, said Lundbeck aimed to add another one or two drugs in clinical testing phase to its portfolio this year.

($1 = 0.8112 euros)

By Teis Jensen and Jacob Gronholt-Pedersen

Source: Reuters

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach